TDMS Study 96007-01 Pathology Tables
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/01/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 12:01:01
FINAL #3/RATS
Facility: Battelle Columbus Laboratory
Chemical CAS #: 57465-28-8
Lock Date: 01/09/01
Cage Range: All
Reasons For Removal: 25022 Accidently Killed 25018 Dosing Accident
25019 Moribund Sacrifice 25020 Natural Death
25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include 001 0 NG/KG
Include 003 30 NG/KG
Include 004 100 NG/KG
Include 005 175 NG/KG
Include 006 300 NG/KG
Include 007 550 NG/KG
Include 008 1000 NG/KG
Include 009 1000 NG/KG/STOP
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 1
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/01/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 12:01:01
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG/KG 30 NG/KG 100 175 300 550
NG/KG NG/KG NG/KG NG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 98 98 98 98 98 98
Early Deaths
Moribund Sacrifice 25 18 21 19 27 18
Natural Death 10 9 6 11 9 12
Accidently Killed 1 3
Dosing Accident 2 1 1
Survivors
Natural Death 1 1
Terminal Sacrifice 15 24 25 22 16 23
Animals Examined Microscopically 53 55 53 53 53 53
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (52) (55) (53) (53) (53) (52)
Hemorrhage 1 [3.0]
Hyperplasia, Focal, Squamous 1 [1.0]
Muscularis, Degeneration 1 [2.0]
Muscularis, Inflammation 2 [1.0] 1 [1.0] 1 [1.0] 1 [1.0] 2 [1.5]
Periesophageal Tissue, Inflammation,
Suppurative 1 [3.0]
Intestine Large, Colon (52) (55) (53) (53) (53) (51)
Hyperplasia, Adenomatous 1 [3.0]
Inflammation 1 [2.0]
Parasite Metazoan 1 2 1
Intestine Large, Rectum (52) (55) (53) (52) (53) (52)
Infiltration Cellular, Lymphocyte 1 [2.0]
Inflammation, Chronic Active 1 [2.0]
Mineralization 1 [2.0]
Parasite Metazoan 2 2 3 1
Artery, Inflammation, Chronic Active 1 [3.0]
Intestine Large, Cecum (52) (54) (53) (51) (53) (52)
Edema 1 [2.0]
Hyperplasia, Lymphoid 1 [2.0]
Inflammation 1 [1.0]
Intestine Small, Duodenum (52) (55) (52) (53) (53) (51)
Erosion 1 [2.0]
Intestine Small, Ileum (52) (54) (52) (51) (53) (52)
Hyperplasia, Lymphoid 1 [2.0]
Mineralization 1 [2.0]
Epithelium, Hyperplasia 1 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 2
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/01/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 12:01:01
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG/KG 30 NG/KG 100 175 300 550
NG/KG NG/KG NG/KG NG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Serosa, Inflammation, Chronic Active 1 [3.0]
Liver (53) (55) (53) (53) (53) (51)
Angiectasis 3 [1.3] 8 [1.4] 4 [1.0] 1 [2.0] 1 [2.0] 2 [1.5]
Basophilic Focus 2 4 6 7 2 3
Basophilic Focus, Multiple 5 6 4 6 2 2
Cholangiofibrosis 1 [2.0] 1 [2.0] 1 [2.0] 3 [1.7] 13 [1.8]
Clear Cell Focus 1 1
Clear Cell Focus, Multiple 1
Cytoplasmic Alteration 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0]
Degeneration, Cystic 1 [1.0] 1 [2.0]
Eosinophilic Focus 6 4 7 4 2 3
Eosinophilic Focus, Multiple 5 6 6 17 15 21
Fatty Change, Diffuse 5 [1.2] 7 [1.0] 14 [1.4] 22 [1.1] 30 [1.1] 45 [1.4]
Fatty Change, Focal 2 [1.5] 6 [1.3] 8 [1.5] 6 [1.5] 3 [1.7] 2 [1.0]
Hematopoietic Cell Proliferation 1 [2.0]
Hepatocyte, Multinucleate 2 [1.0] 10 [1.1] 14 [1.0] 19 [1.3] 46 [1.5]
Hepatodiaphragmatic Nodule 1 1 1
Hyperplasia, Nodular 1 3 26
Inflammation 36 [1.1] 40 [1.1] 49 [1.2] 50 [1.2] 51 [1.2] 51 [1.4]
Mixed Cell Focus 4 6 7 3 3
Mixed Cell Focus, Multiple 17 18 25 29 30 26
Necrosis 4 [2.3] 2 [2.0] 5 [1.6] 8 [2.1] 11 [1.9] 15 [2.0]
Pigmentation 1 [1.0] 11 [1.3] 41 [1.2] 39 [1.6] 48 [1.9] 51 [2.3]
Toxic Hepatopathy 6 [1.2] 22 [1.0] 27 [1.0] 39 [1.3] 51 [2.4]
Vacuolization Cytoplasmic 1 [1.0]
Artery, Inflammation, Chronic Active 1 [2.0] 1 [2.0] 1 [2.0]
Bile Duct, Cyst 3 [1.7] 6 [2.3] 2 [2.0] 3 [2.7] 8 [2.0]
Bile Duct, Fibrosis 4 [1.0] 4 [1.5] 3 [1.3] 2 [1.0] 1 [1.0] 4 [1.0]
Bile Duct, Hyperplasia 3 [1.3] 7 [1.6] 7 [1.6] 13 [1.4] 14 [1.2] 45 [1.8]
Hepatocyte, Degeneration 3 [2.3] 1 [2.0] 1 [2.0] 1 [1.0] 1 [1.0]
Hepatocyte, Hypertrophy 23 [1.1] 32 [1.2] 36 [1.3] 42 [1.4] 50 [2.3]
Oval Cell, Hyperplasia 1 [1.0] 6 [1.2] 7 [1.1] 10 [1.2] 38 [1.8]
Portal, Fibrosis 2 [2.0] 1 [1.0]
Serosa, Inflammation 1 [2.0]
Mesentery (1) (4) (2) (7) (13)
Inflammation, Chronic Active 1 [4.0]
Artery, Inflammation, Chronic Active 2 [3.0] 2 [3.5] 6 [3.2] 10 [2.6]
Fat, Necrosis 1 [3.0] 1 [3.0] 1 [3.0]
Oral Mucosa (1) (1) (3) (4) (2) (6)
Gingival, Hyperplasia, Squamous 1 [2.0] 2 [1.0] 2 [2.0] 4 [1.5]
Pancreas (51) (55) (53) (53) (53) (52)
Basophilic Focus 1 1
Cyst 1 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 3
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/01/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 12:01:01
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG/KG 30 NG/KG 100 175 300 550
NG/KG NG/KG NG/KG NG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Inflammation, Chronic Active 5 [1.6] 1 [1.0] 3 [2.0] 4 [1.3] 4 [1.8] 6 [2.3]
Acinus, Atrophy 5 [2.0] 3 [1.3] 2 [2.5] 7 [1.6] 2 [2.5] 11 [2.2]
Acinus, Hyperplasia 1 [2.0] 1 [3.0] 1 [2.0] 1 [2.0]
Acinus, Vacuolization Cytoplasmic 1 [1.0] 4 [1.5] 9 [1.0] 20 [1.1]
Artery, Inflammation, Chronic Active 4 [2.0] 2 [3.0] 4 [2.5] 8 [2.5] 15 [2.5]
Artery, Mineralization 1 [2.0] 1 [2.0]
Duct, Hyperplasia 1 [4.0]
Duct, Inflammation, Chronic Active 2 [3.0]
Salivary Glands (51) (54) (53) (51) (52) (51)
Atrophy 1 [1.0] 1 [2.0]
Cyst 1 [2.0] 1 [2.0]
Inflammation, Acute 1 [1.0]
Inflammation, Chronic Active 1 [2.0] 1 [2.0]
Stomach, Forestomach (52) (55) (53) (53) (53) (51)
Edema 1 [3.0] 1 [2.0] 1 [2.0]
Erosion 1 [1.0]
Hyperkeratosis 3 [1.7] 1 [2.0] 1 [1.0] 3 [1.7] 1 [2.0]
Hyperplasia, Squamous 3 [1.7] 4 [2.0] 6 [1.8] 2 [2.0] 5 [1.8] 6 [1.7]
Inflammation, Acute 1 [1.0]
Inflammation, Chronic Active 1 [3.0] 2 [2.0] 1 [2.0] 1 [2.0]
Mineralization 1 [2.0] 1 [3.0] 1 [2.0] 1 [2.0]
Necrosis, Focal 1 [2.0]
Ulcer 3 [2.0] 1 [2.0] 1 [2.0] 3 [2.3] 2 [2.0]
Stomach, Glandular (51) (53) (53) (53) (53) (51)
Erosion 1 [2.0] 1 [2.0] 1 [2.0]
Metaplasia, Focal 1 [2.0]
Mineralization 1 [2.0] 1 [3.0] 1 [1.0]
Tooth (12) (12) (10) (9) (10) (9)
Peridontal Tissue, Inflammation, Chronic
Active 2 [2.5] 1 [4.0]
Peridontal Tissue, Inflammation, Suppurative 10 [1.3] 12 [1.3] 10 [1.4] 9 [1.4] 10 [1.4] 8 [1.8]
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (53) (55) (53) (53) (53) (53)
Aorta, Mineralization 3 [1.3] 1 [3.0] 1 [3.0] 2 [1.0]
Heart (52) (54) (53) (53) (53) (51)
Cardiomyopathy 9 [1.0] 16 [1.1] 17 [1.1] 16 [1.2] 24 [1.1] 28 [1.1]
Degeneration 1 [2.0] 1 [3.0] 1 [3.0]
Inflammation 1 [2.0]
Mineralization 1 [2.0] 1 [2.0] 1 [2.0]
Thrombosis 1 [2.0] 1 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 4
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/01/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 12:01:01
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG/KG 30 NG/KG 100 175 300 550
NG/KG NG/KG NG/KG NG/KG
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM - CONT
Artery, Inflammation, Chronic Active 1 [2.0]
Epicardium, Inflammation, Chronic Active 1 [3.0]
Epicardium, Inflammation, Suppurative 2 [2.0] 1 [4.0]
Myocardium, Inflammation 1 [3.0] 1 [1.0]
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (52) (55) (53) (53) (53) (52)
Angiectasis 11 [1.5] 13 [1.5] 25 [1.5] 19 [1.7] 20 [1.5] 8 [1.4]
Atrophy 1 [1.0] 3 [2.3] 5 [1.2] 3 [1.0] 5 [1.6] 19 [1.8]
Degeneration, Cystic 11 [2.1] 14 [2.4] 10 [2.0] 14 [2.8] 14 [2.1] 16 [2.3]
Hyperplasia 23 [1.9] 21 [2.4] 27 [2.1] 25 [2.0] 25 [2.4] 31 [2.7]
Hypertrophy 34 [1.9] 41 [2.0] 40 [1.9] 41 [2.1] 40 [1.9] 41 [2.0]
Inflammation, Suppurative 1 [1.0]
Mineralization 1 [2.0] 1 [1.0]
Necrosis 1 [2.0] 1 [2.0] 1 [3.0] 1 [2.0] 1 [2.0]
Thrombosis 1 [2.0]
Vacuolization Cytoplasmic 5 [1.2] 3 [1.7] 5 [2.0] 2 [2.0] 9 [1.9] 4 [1.0]
Adrenal Medulla (52) (55) (53) (53) (53) (52)
Angiectasis 2 [2.0] 1 [2.0] 2 [2.5] 2 [2.5]
Hyperplasia 8 [1.5] 18 [2.0] 11 [1.7] 11 [2.0] 12 [1.8] 6 [2.0]
Necrosis 1 [3.0]
Islets, Pancreatic (52) (54) (53) (53) (53) (52)
Hyperplasia 1 [2.0] 2 [2.0] 1 [1.0] 1 [1.0] 1 [1.0]
Parathyroid Gland (47) (50) (48) (46) (49) (47)
Hyperplasia 1 [2.0] 1 [2.0] 2 [1.5] 1 [3.0] 1 [1.0]
Pituitary Gland (51) (54) (53) (53) (53) (53)
Angiectasis 14 [2.1] 15 [2.1] 22 [2.2] 12 [2.3] 16 [2.3] 19 [2.3]
Cyst 3 [2.3] 1 [2.0] 1 [1.0] 2 [2.5]
Cytoplasmic Alteration 1 [2.0] 1 [2.0] 1 [2.0] 3 [2.0] 1 [2.0]
Inflammation, Focal, Granulomatous 1 [2.0]
Necrosis 1 [2.0]
Pigmentation 1 [2.0]
Vacuolization Cytoplasmic 1 [2.0] 1 [1.0]
Pars Distalis, Hyperplasia 18 [1.9] 20 [2.5] 23 [2.2] 17 [2.1] 21 [1.9] 26 [2.2]
Thyroid Gland (52) (55) (52) (51) (52) (50)
Angiectasis 1 [2.0] 4 [2.0]
Cyst 1 [2.0] 1 [2.0]
C-Cell, Hyperplasia 12 [1.9] 21 [1.7] 17 [1.5] 19 [1.8] 18 [1.9] 16 [1.9]
Follicle, Cyst 1 [2.0]
Follicular Cell, Hyperplasia 1 [1.0] 1 [1.0]
Follicular Cell, Hypertrophy 9 [1.3] 13 [1.2] 13 [1.5] 17 [1.1] 28 [1.5] 26 [1.3]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 5
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/01/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 12:01:01
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG/KG 30 NG/KG 100 175 300 550
NG/KG NG/KG NG/KG NG/KG
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (50) (55) (52) (50) (53) (52)
Hyperplasia 1 [2.0]
Hyperplasia, Squamous 1 [1.0]
Inflammation 28 [1.5] 36 [1.4] 39 [1.7] 28 [1.6] 30 [1.4] 27 [1.3]
Duct, Cyst 29 [1.9] 32 [2.0] 34 [2.0] 37 [1.9] 39 [2.0] 42 [2.2]
Ovary (52) (54) (53) (52) (52) (52)
Atrophy 45 [4.0] 49 [4.0] 46 [4.0] 45 [4.0] 47 [4.0] 46 [4.0]
Cyst 12 [2.0] 17 [2.2] 17 [2.4] 15 [2.3] 16 [2.1] 18 [2.1]
Inflammation, Chronic Active 1 [2.0] 1 [3.0]
Inflammation, Suppurative 1 [1.0] 2 [2.5]
Necrosis 1 [4.0]
Artery, Inflammation, Chronic Active 1 [3.0] 1 [2.0]
Oviduct (1) (1) (1) (3)
Cyst 1 [4.0]
Inflammation, Chronic Active 1 [3.0]
Inflammation, Suppurative 1 [2.0] 1 [1.0] 2 [2.5]
Uterus (52) (55) (53) (52) (53) (52)
Adenomyosis 1 [2.0] 1 [4.0] 2 [2.5]
Cyst 1 [3.0]
Erosion 1 [2.0]
Hemorrhage 1 [2.0] 2 [3.0] 1 [3.0]
Inflammation, Chronic Active 2 [3.0] 1 [4.0] 1 [2.0]
Inflammation, Granulomatous 1 [2.0]
Inflammation, Suppurative 12 [1.8] 12 [1.8] 11 [1.6] 16 [2.0] 10 [1.6] 6 [2.2]
Metaplasia, Squamous 26 [1.6] 33 [1.9] 25 [2.1] 28 [2.3] 29 [1.8] 27 [2.2]
Thrombosis 1 [2.0] 1 [3.0]
Ulcer 1 [2.0]
Vacuolization Cytoplasmic 2 [2.0]
Artery, Inflammation, Chronic Active 1 [3.0] 1 [3.0]
Cervix, Cyst 1 [2.0]
Cervix, Hyperplasia, Stromal 1 [3.0]
Endometrium, Hyperplasia, Cystic 23 [1.7] 33 [2.1] 28 [1.8] 24 [2.5] 26 [2.0] 32 [2.2]
Epithelium, Hyperplasia 1 [3.0] 1 [3.0]
Epithelium, Necrosis 1 [2.0] 1 [2.0]
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 6
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/01/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 12:01:01
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG/KG 30 NG/KG 100 175 300 550
NG/KG NG/KG NG/KG NG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (53) (55) (53) (53) (53) (53)
Angiectasis 1 [2.0]
Fibrosis 1 [3.0]
Hyperplasia 47 [3.4] 37 [3.2] 35 [3.3] 44 [3.3] 45 [3.2] 46 [3.2]
Lymph Node (2) (6) (6) (6) (4) (7)
Ectasia 1 [2.0]
Deep Cervical, Ectasia 1 [2.0]
Inguinal, Hyperplasia, Plasma Cell 1 [2.0]
Inguinal, Pigmentation 1 [2.0]
Lumbar, Ectasia 2 [2.0]
Lumbar, Hyperplasia 1 [2.0]
Lumbar, Hyperplasia, Lymphoid 1 [2.0]
Lumbar, Hyperplasia, Plasma Cell 2 [2.5] 1 [3.0]
Mediastinal, Ectasia 2 [1.5] 3 [2.0]
Mediastinal, Hemorrhage 2 [2.0] 1 [2.0] 1 [2.0]
Mediastinal, Hyperplasia, Lymphoid 1 [3.0]
Mediastinal, Hyperplasia, Plasma Cell 1 [2.0] 1 [3.0]
Mediastinal, Inflammation, Suppurative 1 [2.0]
Pancreatic, Hyperplasia, Plasma Cell 1 [2.0]
Lymph Node, Mandibular (52) (53) (51) (51) (52) (51)
Ectasia 1 [2.0] 1 [3.0] 4 [2.0] 4 [2.5] 4 [2.0] 4 [2.5]
Hemorrhage 1 [2.0]
Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] 1 [2.0] 2 [2.0]
Hyperplasia, Plasma Cell 18 [2.2] 24 [2.0] 31 [2.2] 21 [2.3] 29 [2.0] 11 [2.2]
Lymph Node, Mesenteric (52) (54) (52) (52) (53) (51)
Atrophy 1 [3.0]
Ectasia 1 [2.0] 1 [2.0]
Hemorrhage 2 [2.0] 3 [2.0] 1 [2.0] 1 [2.0]
Hyperplasia, Histiocytic 3 [1.7] 1 [2.0]
Hyperplasia, Plasma Cell 1 [2.0]
Pigmentation 1 [1.0]
Spleen (52) (55) (52) (53) (53) (52)
Hematopoietic Cell Proliferation 39 [1.7] 43 [1.6] 46 [1.4] 45 [1.5] 41 [1.7] 42 [1.4]
Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] 1 [3.0]
Necrosis 1 [2.0]
Pigmentation 49 [1.3] 50 [1.4] 51 [1.5] 51 [1.4] 52 [1.5] 52 [1.5]
Lymphoid Follicle, Atrophy 5 [2.6] 3 [2.0] 2 [1.5] 5 [2.0] 3 [2.3]
Red Pulp, Atrophy 4 [2.0] 1 [2.0] 1 [2.0]
Thymus (50) (52) (46) (48) (41) (49)
Atrophy 37 [2.5] 34 [2.6] 41 [2.8] 45 [2.8] 36 [3.3] 47 [3.5]
Fibrosis 1 [2.0]
Hemorrhage 1 [3.0] 1 [1.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 7
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/01/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 12:01:01
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG/KG 30 NG/KG 100 175 300 550
NG/KG NG/KG NG/KG NG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Inflammation 1 [3.0] 1 [3.0]
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (52) (55) (53) (53) (53) (52)
Cyst 8 [1.8] 3 [1.7] 1 [4.0] 4 [3.3] 5 [2.6] 1 [2.0]
Fibrosis, Focal 1 [2.0]
Hyperplasia 32 [1.4] 33 [1.4] 30 [1.4] 29 [1.2] 21 [1.2] 23 [1.1]
Inflammation, Chronic Active 1 [3.0] 2 [3.0] 2 [2.0]
Inflammation, Granulomatous 2 [2.0] 2 [3.0] 1 [2.0]
Skin (52) (55) (53) (53) (53) (53)
Cyst, Squamous 1 [2.0] 1 [3.0]
Ulcer 1 [2.0]
Dermis, Inflammation, Focal 1 [2.0]
Subcutaneous Tissue, Inflammation,
Suppurative 1 [2.0]
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (53) (55) (53) (53) (53) (53)
Inflammation, Chronic Active 1 [2.0]
Osteopetrosis 1 [2.0] 2 [2.0]
Cartilage, Hypertrophy, Focal 1 [2.0]
Skeletal Muscle (1) (1) (1)
Inflammation, Chronic Active 1 [3.0]
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (53) (55) (53) (53) (53) (53)
Hemorrhage 1 [3.0]
Hydrocephalus 1 [1.0] 2 [2.0] 1 [2.0]
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (53) (55) (53) (53) (53) (51)
Congestion 1 [3.0] 1 [2.0] 1 [2.0]
Infiltration Cellular, Histiocyte 41 [1.7] 49 [1.7] 45 [1.7] 48 [1.6] 45 [1.6] 49 [1.7]
Inflammation, Chronic Active 5 [1.4] 3 [1.3] 1 [2.0] 1 [2.0]
Inflammation, Granulomatous 3 [1.7] 2 [1.5]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 8
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/01/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 12:01:01
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG/KG 30 NG/KG 100 175 300 550
NG/KG NG/KG NG/KG NG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - CONT
Inflammation, Suppurative 1 [2.0]
Metaplasia, Squamous 1 [2.0] 1 [2.0] 2 [1.5] 3 [2.3] 9 [1.7]
Mineralization 1 [3.0] 1 [3.0] 1 [2.0]
Thrombosis 2 [2.5] 1 [2.0]
Alveolar Epithelium, Hyperplasia 12 [1.1] 1 [1.0] 1 [3.0] 2 [1.0]
Alveolar Epithelium, Metaplasia, Bronchiolar 29 [1.3] 34 [1.6] 41 [1.8] 39 [1.7] 47 [2.1]
Serosa, Fibrosis 2 [1.5]
Serosa, Inflammation, Chronic Active 1 [2.0]
Serosa, Inflammation, Suppurative 2 [2.5] 1 [3.0] 1 [3.0]
Vein, Thrombosis 1 [3.0]
Nose (53) (54) (52) (53) (52) (53)
Nasolacrimal Duct, Inflammation 1 [2.0] 1 [2.0] 1 [2.0]
Nasolacrimal Duct, Glands, Hyperplasia 1 [4.0]
Nasolacrimal Duct, Respiratory Epithelium,
Hyperplasia 1 [2.0]
Nasopharyngeal Duct, Inflammation,
Suppurative 1 [4.0] 1 [3.0]
Olfactory Epithelium, Inflammation,
Suppurative 1 [3.0] 1 [3.0]
Respiratory Epithelium, Hyperplasia 2 [2.5] 1 [2.0] 1 [2.0] 2 [2.0] 2 [2.5]
Respiratory Epithelium, Inflammation,
Suppurative 1 [3.0] 1 [2.0] 1 [3.0]
Respiratory Epithelium, Metaplasia 1 [4.0] 1 [2.0]
Turbinate, Cyst 1 [1.0]
Turbinate, Inflammation, Suppurative 2 [2.0] 1 [2.0] 1 [1.0] 2 [2.5]
Trachea (53) (55) (53) (53) (53) (52)
Inflammation 1 [2.0]
Peritracheal Tissue, Inflammation 1 [3.0]
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1)
Inflammation 1 [1.0]
Eye (51) (55) (53) (53) (53) (52)
Atrophy 1 [3.0] 1 [3.0]
Cataract 1 [3.0] 1 [3.0]
Edema 1 [3.0]
Anterior Chamber, Inflammation, Suppurative 1 [3.0]
Anterior Chamber, Ciliary Body, Cornea,
Inflammation, Suppurative 1 [2.0]
Cornea, Inflammation, Suppurative 1 [3.0]
Retina, Atrophy 3 [2.3] 1 [3.0] 1 [3.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 9
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/01/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 12:01:01
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG/KG 30 NG/KG 100 175 300 550
NG/KG NG/KG NG/KG NG/KG
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM - CONT
Retina, Degeneration 1 [2.0]
Harderian Gland (53) (53) (53) (53) (53) (52)
Inflammation 2 [1.0] 3 [1.0] 6 [1.2] 6 [1.2] 3 [1.0] 3 [1.0]
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (53) (55) (53) (53) (53) (52)
Calculus Micro Observation Only 1 1 1
Casts Protein 4 [1.3] 3 [1.3] 1 [1.0] 6 [1.2]
Cyst 2 [1.5]
Inflammation, Chronic Active 2 [2.0] 2 [2.0] 1 [3.0] 1 [3.0] 1 [1.0] 1 [2.0]
Inflammation, Suppurative 3 [1.0] 1 [3.0]
Mineralization 32 [1.0] 39 [1.0] 44 [1.0] 44 [1.0] 44 [1.0] 39 [1.1]
Necrosis 1 [2.0] 1 [3.0] 1 [3.0]
Nephropathy 32 [1.3] 29 [1.3] 38 [1.5] 35 [1.3] 38 [1.5] 42 [2.1]
Papilla, Angiectasis 1 [2.0]
Pelvis, Dilatation 2 [2.0] 1 [3.0] 1 [2.0]
Pelvis, Inflammation, Chronic Active 2 [2.5] 2 [2.5] 2 [2.5]
Pelvis, Inflammation, Suppurative 2 [1.0] 3 [2.0]
Renal Tubule, Accumulation, Hyaline Droplet 1 [3.0]
Renal Tubule, Dilatation 1 [2.0]
Transitional Epithelium, Hyperplasia 4 [2.0] 2 [2.5] 8 [1.9] 4 [2.5] 8 [1.6] 8 [2.3]
Ureter (1)
Mineralization 1 [3.0]
Transitional Epithelium, Hyperplasia 1 [2.0]
Urinary Bladder (51) (54) (53) (52) (52) (52)
Edema 1 [3.0]
Hemorrhage 1 [2.0]
Inflammation 4 [1.5] 6 [1.5] 10 [1.4] 6 [2.2] 7 [1.6] 4 [1.0]
Transitional Epithelium, Hyperplasia 1 [2.0] 1 [3.0] 1 [2.0] 2 [2.5] 1 [3.0] 2 [2.5]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 10
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/01/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 12:01:01
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 1000 1000 NG/
NG/KG KG/STOP
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 98 50
Early Deaths
Natural Death 12 6
Moribund Sacrifice 34 15
Dosing Accident 1
Survivors
Terminal Sacrifice 7 28
Animals Examined Microscopically 53 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (52) (50)
Cyst 1 [2.0]
Muscularis, Inflammation 1 [1.0]
Intestine Large, Colon (53) (50)
Parasite Metazoan 1
Intestine Large, Rectum (53) (50)
Parasite Metazoan 1 1
Intestine Small, Duodenum (53) (50)
Erosion 2 [1.5]
Ulcer 1 [3.0]
Epithelium, Hyperplasia 1 [2.0]
Intestine Small, Jejunum (53) (50)
Hyperplasia, Lymphoid 1 [2.0]
Liver (53) (50)
Angiectasis 2 [2.0] 8 [1.5]
Basophilic Focus 2 7
Basophilic Focus, Multiple 3 9
Cholangiofibrosis 22 [2.3] 1 [1.0]
Clear Cell Focus 1
Clear Cell Focus, Multiple 4
Cytoplasmic Alteration 1 [3.0]
Degeneration, Cystic 2 [2.0] 3 [2.0]
Eosinophilic Focus 6 3
Eosinophilic Focus, Multiple 11 9
Fatty Change, Diffuse 47 [1.8] 12 [1.3]
Fatty Change, Focal 11 [1.5]
Hepatocyte, Multinucleate 49 [1.7] 20 [1.0]
Hepatodiaphragmatic Nodule 1 1
Hyperplasia, Nodular 39
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 11
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/01/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 12:01:01
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 1000 1000 NG/
NG/KG KG/STOP
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Inflammation 51 [1.2] 46 [1.2]
Mixed Cell Focus 4 1
Mixed Cell Focus, Multiple 5 35
Multinucleated 1 [1.0]
Necrosis 17 [2.2] 4 [2.8]
Pigmentation 48 [2.5] 48 [1.8]
Toxic Hepatopathy 49 [3.4] 15 [1.2]
Bile Duct, Cyst 12 [2.0] 5 [2.2]
Bile Duct, Fibrosis 5 [1.2] 4 [1.0]
Bile Duct, Hyperplasia 45 [2.5] 16 [1.4]
Bile Duct, Inflammation 1 [2.0]
Hepatocyte, Degeneration 7 [2.3]
Hepatocyte, Hypertrophy 49 [3.4] 21 [1.4]
Oval Cell, Hyperplasia 40 [2.2] 1 [1.0]
Portal, Fibrosis 10 [2.1]
Serosa, Inflammation 1 [1.0]
Mesentery (11)
Inflammation, Chronic Active 3 [2.7]
Artery, Inflammation, Chronic Active 7 [2.7]
Fat, Necrosis 1 [2.0]
Oral Mucosa (11) (6)
Gingival, Cyst, Squamous 1 [2.0]
Gingival, Hyperplasia, Squamous 3 [2.7] 3 [2.3]
Pharyngeal, Hyperplasia, Squamous 1 [4.0]
Pancreas (51) (48)
Basophilic Focus 1
Cyst 1 [2.0]
Inflammation, Chronic Active 13 [2.2] 4 [1.5]
Necrosis 1 [2.0]
Acinus, Atrophy 18 [2.1] 7 [1.4]
Acinus, Vacuolization Cytoplasmic 23 [1.4] 1 [1.0]
Artery, Inflammation, Chronic Active 11 [2.9] 1 [2.0]
Duct, Dilatation 2 [4.0]
Duct, Hyperplasia 1 [2.0]
Salivary Glands (51) (49)
Atrophy 1 [2.0]
Cyst 2 [3.0]
Inflammation, Acute 1 [2.0]
Stomach, Forestomach (53) (50)
Edema 2 [2.0]
Hyperkeratosis 2 [1.5]
Hyperplasia, Squamous 8 [1.9] 2 [1.5]
Mineralization 2 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 12
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/01/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 12:01:01
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 1000 1000 NG/
NG/KG KG/STOP
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Ulcer 2 [2.0]
Stomach, Glandular (53) (50)
Erosion 1 [2.0]
Inflammation, Chronic Active 1 [1.0]
Mineralization 1 [2.0]
Artery, Inflammation, Chronic Active 1 [2.0]
Glands, Ectasia 1 [2.0]
Glands, Hyperplasia 1 [2.0]
Tooth (19) (12)
Peridontal Tissue, Fibrosis 1 [3.0] 1 [3.0]
Peridontal Tissue, Inflammation, Suppurative 18 [1.6] 11 [1.6]
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (53) (50)
Aorta, Mineralization 1 [2.0]
Heart (51) (50)
Cardiomyopathy 32 [1.2] 15 [1.2]
Mineralization 1 [2.0]
Thrombosis 1 [3.0] 1 [2.0]
Artery, Inflammation, Chronic Active 1 [1.0]
Endocardium, Myocardium, Inflammation, Acute 1 [3.0]
Epicardium, Inflammation, Chronic Active 1 [2.0]
Epicardium, Inflammation, Suppurative 1 [4.0]
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (53) (50)
Angiectasis 1 [2.0] 14 [1.7]
Atrophy 30 [2.2] 9 [1.7]
Degeneration, Cystic 10 [2.2] 20 [2.4]
Hyperplasia 24 [2.5] 26 [2.0]
Hypertrophy 41 [1.8] 42 [2.4]
Inflammation, Suppurative 1 [2.0]
Mineralization 1 [2.0]
Necrosis 2 [1.5] 2 [1.5]
Vacuolization Cytoplasmic 17 [1.9] 6 [1.5]
Adrenal Medulla (53) (50)
Hyperplasia 1 [2.0] 9 [1.4]
Parathyroid Gland (46) (44)
Cyst 1 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 13
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/01/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 12:01:01
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 1000 1000 NG/
NG/KG KG/STOP
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Hyperplasia 2 [1.5]
Pituitary Gland (53) (48)
Angiectasis 9 [2.1] 14 [2.3]
Cyst 1 [1.0] 1 [3.0]
Cytoplasmic Alteration 1 [2.0]
Pars Distalis, Hyperplasia 17 [1.9] 17 [2.0]
Thyroid Gland (48) (47)
Angiectasis 1 [2.0]
Atrophy 1 [4.0]
Infiltration Cellular, Lymphocyte 1 [2.0]
C-Cell, Hyperplasia 19 [1.7] 18 [1.8]
Follicular Cell, Hyperplasia 1 [4.0]
Follicular Cell, Hypertrophy 16 [1.3] 22 [1.4]
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (51) (48)
Inflammation 22 [1.3] 32 [1.6]
Duct, Cyst 45 [2.3] 39 [1.9]
Ovary (53) (50)
Atrophy 33 [3.9] 47 [4.0]
Cyst 11 [2.5] 17 [2.3]
Oviduct (1) (2)
Inflammation, Suppurative 1 [3.0] 2 [3.0]
Uterus (53) (50)
Hemorrhage 1 [2.0]
Inflammation, Chronic Active 1 [4.0]
Inflammation, Suppurative 4 [2.5] 11 [2.2]
Metaplasia, Squamous 11 [2.4] 28 [2.0]
Endometrium, Hyperplasia, Cystic 9 [1.8] 31 [2.0]
Epithelium, Hyperplasia 1 [2.0]
Vagina (1)
Cyst 1 [3.0]
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 14
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/01/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 12:01:01
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 1000 1000 NG/
NG/KG KG/STOP
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Bone Marrow (53) (50)
Atrophy 1 [3.0]
Hyperplasia 46 [3.3] 34 [3.1]
Lymph Node (12) (2)
Iliac, Ectasia 1 [2.0]
Mediastinal, Angiectasis 1 [2.0]
Mediastinal, Ectasia 5 [1.8]
Mediastinal, Hemorrhage 6 [2.0]
Mediastinal, Hyperplasia, Lymphoid 1 [2.0]
Mediastinal, Pigmentation 2 [2.0]
Pancreatic, Hemorrhage 1 [1.0]
Lymph Node, Mandibular (51) (49)
Atrophy 1 [3.0]
Ectasia 3 [2.3] 3 [2.3]
Hemorrhage 1 [2.0]
Hyperplasia, Lymphoid 1 [2.0]
Hyperplasia, Plasma Cell 15 [2.1] 21 [2.3]
Lymph Node, Mesenteric (53) (50)
Atrophy 1 [3.0] 2 [1.5]
Ectasia 1 [2.0]
Hemorrhage 2 [1.5]
Hyperplasia, Histiocytic 1 [2.0] 1 [2.0]
Hyperplasia, Lymphoid 2 [2.0]
Hyperplasia, Plasma Cell 1 [2.0]
Spleen (52) (50)
Hematopoietic Cell Proliferation 37 [1.6] 37 [1.5]
Hyperplasia, Lymphoid 3 [2.0]
Pigmentation 50 [1.3] 50 [1.6]
Lymphoid Follicle, Atrophy 6 [2.3] 4 [2.5]
Red Pulp, Atrophy 2 [2.5]
Thymus (44) (43)
Atrophy 41 [3.5] 39 [3.0]
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (53) (50)
Cyst 1 [3.0] 13 [2.7]
Hyperplasia 9 [1.4] 22 [1.1]
Skin (53) (50)
Cyst, Squamous 1 [3.0] 2 [2.5]
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 15
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/01/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 12:01:01
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 1000 1000 NG/
NG/KG KG/STOP
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1)
Inflammation, Chronic Active 1 [2.0]
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (53) (50)
Hemorrhage 1 [2.0]
Inflammation, Focal, Suppurative 1 [3.0]
Necrosis, Focal 1 [3.0]
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (51) (50)
Hemorrhage 1 [2.0] 1 [2.0]
Infiltration Cellular, Histiocyte 42 [1.5] 42 [1.5]
Inflammation, Chronic Active 2 [2.5]
Metaplasia, Squamous 4 [1.8]
Mineralization 1 [2.0] 1 [2.0]
Alveolar Epithelium, Metaplasia, Bronchiolar 40 [1.9] 32 [1.5]
Serosa, Inflammation, Suppurative 1 [3.0]
Nose (53) (50)
Goblet Cell, Respiratory Epithelium,
Hyperplasia 1 [2.0]
Nasolacrimal Duct, Inflammation 1 [3.0] 1 [3.0]
Nasolacrimal Duct, Respiratory Epithelium,
Hyperplasia 1 [3.0]
Nasopharyngeal Duct, Respiratory Epithelium,
Hyperplasia 1 [3.0]
Respiratory Epithelium, Hyperplasia 1 [2.0] 1 [2.0]
Turbinate, Cyst 1 [2.0]
Turbinate, Inflammation, Suppurative 4 [2.3] 1 [1.0]
Vomeronasal Organ, Vacuolization Cytoplasmic 1 [2.0]
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (52) (50)
Anterior Chamber, Inflammation, Suppurative 1 [3.0] 1 [3.0]
Cornea, Inflammation, Suppurative 2 [2.5] 1 [3.0]
Optic Nerve, Degeneration 1 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 16
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/01/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 12:01:01
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 1000 1000 NG/
NG/KG KG/STOP
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM - CONT
Retina, Atrophy 4 [2.5]
Harderian Gland (52) (50)
Inflammation 6 [1.2] 9 [1.1]
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (53) (50)
Casts Protein 2 [1.5] 3 [1.7]
Inflammation, Suppurative 2 [2.0]
Mineralization 37 [1.0] 45 [1.0]
Necrosis 1 [3.0]
Nephropathy 47 [2.1] 38 [1.4]
Papilla, Necrosis 1 [2.0]
Pelvis, Dilatation 2 [3.5] 1 [2.0]
Pelvis, Hemorrhage 1 [3.0]
Pelvis, Inflammation, Chronic Active 1 [3.0] 1 [3.0]
Pelvis, Metaplasia, Squamous 1 [2.0]
Transitional Epithelium, Hyperplasia 11 [2.0] 2 [2.0]
Ureter (3)
Inflammation 1 [2.0]
Metaplasia, Squamous 2 [2.5]
Mineralization 2 [3.5]
Transitional Epithelium, Hyperplasia 3 [3.0]
Urinary Bladder (53) (50)
Inflammation 6 [1.5] 3 [1.3]
Metaplasia, Squamous 1 [2.0]
Transitional Epithelium, Hyperplasia 2 [3.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 17
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------